2. Search Result
Search Result
Results for "

Inhibitor peptide

" in MedChemExpress (MCE) Product Catalog:

1315

Inhibitors & Agonists

3

Screening Libraries

5

Fluorescent Dyes

24

Biochemical Assay Reagents

896

Peptides

2

MCE Kits

7

Inhibitory Antibodies

70

Natural
Products

4

Recombinant Proteins

25

Isotope-Labeled Compounds

10

Click Chemistry

1

Oligonucleotides

2

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1026
    NFAT Inhibitor-1
    10+ Cited Publications

    VIVIT peptide

    		 Nuclear Factor of activated T Cells (NFAT) Inflammation/Immunology
    NFAT Inhibitor (VIVIT peptide) is an inhibitor of nuclear factor of activated Tcells (NFAT) that selectively inhibits calcineurin-mediated dephosphorylation of NFAT .
    NFAT Inhibitor-1
  • HY-P0081
    Bax inhibitor peptide V5
    15+ Cited Publications

    BIP-V5; BAX Inhibiting peptide V5

    		 Bcl-2 Family Apoptosis Cancer
    Bax inhibitor peptide V5 (BIP-V5) is a Bax-mediated apoptosis inhibitor, used for cancer treatment.
    Bax inhibitor peptide V5
  • HY-P0301A
    SLLK, Control Peptide for TSP1 InhibitorTFA

    		TGF-β Receptor Cancer
    SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.
    SLLK, Control Peptide for TSP1 InhibitorTFA
  • HY-P5960
    PTBP1-RNA-binding inhibitor P6 TFA

    PTBP1 α3-helix derived peptide P6 TFA

    		 DNA/RNA Synthesis Others
    PTBP1-RNA-binding inhibitor P6 (PTBP1 α3-helix derived peptide P6) TFA is a stapled peptide inhibitor of the splicing factor PTBP1, which inhibits alternative splicing events regulated by PTBP1. PTBP1 binds RNA through its RNA recognition motif .
    PTBP1-RNA-binding inhibitor P6 TFA
  • HY-P1111
    Lyn peptide inhibitor

    		Src Interleukin Related Inflammation/Immunology
    Lyn peptide inhibitor (YGYRLRRKWEEKIPNP-NH2) is a potent, cell-permeable Lyn kinase inhibitor that inhibits Lyn-coupled signaling pathways associated with the IL-5 receptor while preserving the integrity of other signals. Lyn peptide inhibitor blocks the activation of Lyn and inhibits the binding of Lyn tyrosine kinase to the βc subunit of the IL-3/GM-CSF/IL-5 receptor. Lyn peptide inhibitor can be used in the research of eosinophilic diseases such as asthma and allergy .
    Lyn peptide inhibitor
  • HY-P6437A
    Drp1 peptide inhibitor P110 TFA

    		Dynamin Cardiovascular Disease Neurological Disease
    Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .
    Drp1 peptide inhibitor P110 TFA
  • HY-P1684
    Peptide P60
    1 Publications Verification

    FOXP3 Inhibitor P60

    		 NF-κB Nuclear Factor of activated T Cells (NFAT) Infection Inflammation/Immunology Cancer
    Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 +CD25 +Foxp3 + T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .
    Peptide P60
  • HY-P1741
    Fibrinogen-Binding Peptide
    1 Publications Verification

    		 Thrombin Cardiovascular Disease
    Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .
    Fibrinogen-Binding Peptide
  • HY-P5910
    Azurin p28 peptide

    		MDM-2/p53 Apoptosis Cancer
    Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .
    Azurin p28 peptide
  • HY-P1292
    PKG inhibitor peptide
    2 Publications Verification

    		 PKG Cancer
    PKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM .
    PKG inhibitor peptide
  • HY-P1029
    MLCK inhibitor peptide 18
    5+ Cited Publications

    		 Myosin CaMK Autophagy Others
    MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
    MLCK inhibitor peptide 18
  • HY-P6437
    Drp1 peptide inhibitor P110

    		Dynamin Cardiovascular Disease Neurological Disease
    Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .
    Drp1 peptide inhibitor P110
  • HY-P1962
    β-Secretase inhibitor

    [Asn670, Sta671, Val672]-Amyloid β peptide (662-675)

    		 Beta-secretase Neurological Disease
    β-Secretase inhibitor ([Asn670, Sta671, Val672]-Amyloid β Peptide (662-675)) is a β-secretase and BACE1 inhibitor (IC50: 25 nM for β-secretase) .
    β-Secretase inhibitor
  • HY-P10950A
    PD-L1 inhibitory peptide TFA

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-L1 inhibitory peptide TFA is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide TFA binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide TFA is promising for research of cancers .
    PD-L1 inhibitory peptide TFA
  • HY-P3695
    VSPPLTLGQLLS

    		FGFR Cancer
    VSPPLTLGQLLS is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation .
    VSPPLTLGQLLS
  • HY-P1369
    DynaMin inhibitory peptide, myristoylated
    1 Publications Verification

    		 Dynamin Neurological Disease
    DynaMin inhibitory peptide, myristoylated is a DynaMin inhibitor to interfere with the binding of amphiphysin with dynamin. DynaMin inhibitory peptide, myristoylated is a membrane-permeant form of the peptide that prevents endocytosis .
    DynaMin inhibitory peptide, myristoylated
  • HY-P10108
    Hexokinase II VDAC binding domain peptide, cell-permeable

    Hxk2VBD peptide, cell-permeable

    		 Hexokinase Neurological Disease
    Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth .
    Hexokinase II VDAC binding domain peptide, cell-permeable
  • HY-P10723
    IL-23R inhibitor peptide-1

    		Interleukin Related Inflammation/Immunology
    IL-23R inhibitor peptide-1 (comp 475) is an interleukin-23 receptor inhibitor, with an IC50 of 0.0069 μM .
    IL-23R inhibitor peptide-1
  • HY-P0301
    SLLK, Control Peptide for TSP1 Inhibitor

    		TGF-β Receptor Cancer
    SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine).
    SLLK, Control Peptide for TSP1 Inhibitor
  • HY-P5107
    Low molecular weight protamine

    LMWP; TDSP5

    		 VEGFR Cancer
    Low molecular weight protamine is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity. Low molecular weight protamine can inhibit tumor growth and is used in cancer research .
    Low molecular weight protamine
  • HY-P4123
    TAT (47-57) GGG-Cys(Npys)

    		MMP Cardiovascular Disease Inflammation/Immunology Cancer
    TAT (47-57) GGG-Cys (Npys) is a cell-penetrating peptide and delivery carrier derived from TAT. TAT (47-57) GGG-Cys (Npys) facilitates the translocation of conjugated drug molecules across cell membranes. TAT (47-57) GGG-Cys (Npys) acts as a delivery carrier for MT1-MMP inhibitors. TAT (47-57) GGG-Cys (Npys) is applicable to research on diseases associated with MT1-MMP activity, such as cancer, arthritis, heart disease, and vascular disorders .
    TAT (47-57) GGG-Cys(Npys)
  • HY-P3244
    D-KLVFFA

    		Amyloid-β Neurological Disease
    D-KLVFFA is the inhibitor of Amyloid-β assembly, with the IC50 of 2.6 μM, that can be used in Alzheimer's disease study .
    D-KLVFFA
  • HY-122543
    PPACK II diTFA

    		Kallikrein Cardiovascular Disease
    PPACK II diTFA is an irreversible and specific glandular and plasma kallikreins inhibitor .
    PPACK II diTFA
  • HY-P1507
    Fibrinogen Binding Inhibitor Peptide

    		Integrin Cardiovascular Disease
    Fibrinogen Binding Inhibitor Peptide is a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). Fibrinogen Binding Inhibitor Peptide is a specific binding site of the ligand for activated glycoprotein (GP) IIb/IIIa.
    Fibrinogen Binding Inhibitor Peptide
  • HY-P1195
    PDZ1 Domain inhibitor peptide

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide
  • HY-P10950
    PD-L1 inhibitory peptide

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers .
    PD-L1 inhibitory peptide
  • HY-P5786
    Heteropodatoxin-1

    HpTx1

    		 Potassium Channel Sodium Channel Neurological Disease
    Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits Nav1.7 and activates Nav1.9 but does not affect Nav1.8 .
    Heteropodatoxin-1
  • HY-P11300
    YKYY

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    YKYY, a antihypertensive peptide, is an Angiotensin I-converting enzyme (ACE) inhibitor with an IC50 of 64.2 μM. YKYY can be isolated for the peptic digest of wakame Undaria pinnatifida. YKYY can be used for hypertension research .
    YKYY
  • HY-P11300A
    YKYY TFA

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    YKYY TFA is a blood pressure-lowering peptide isolated from the digest of Undaria pinnatifida. It is an angiotensin I-converting enzyme (ACE) inhibitor with an IC50 of 64.2 μM. YKYY FTA can be used in hypertension research .
    YKYY TFA
  • HY-P11032
    Mp-4D7-pF2

    		SARS-CoV Virus Protease Infection
    Mp-4D7-pF2, a cell-penetrating bicyclic peptide, is a noncovalent SARS-CoV-2 main protease inhibitor with an IC50 of 4.51 μM. Mp-4D7-pF2 has an antiviral activity against SARS-CoV-2 with no cytotoxicity. Mp-4D7-pF2 can used for COVID-19 infections research .
    Mp-4D7-pF2
  • HY-P10072A
    MK2-IN-5 acetate

    Hsp25 kinase Inhibitor acetate; Mk2 pseudosubstrate acetate

    		 JNK HSP MAPKAPK2 (MK2) p38 MAPK ERK Others
    MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a Mk2 pseudosubstrate (Ki= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation .
    MK2-IN-5 acetate
  • HY-P10485
    Glp-Asn-Pro-AMC

    		Thyroid Hormone Receptor Neurological Disease
    Glp-Asn-Pro-AMC is an inhibitor of thyrotropin-releasing hormone degrading enzyme (TRH-DE) with a Ki value of 0.97 μM .
    Glp-Asn-Pro-AMC
  • HY-P1190
    c-JUN peptide

    		JNK Apoptosis Inflammation/Immunology
    c-JUN peptide is a cell-permeable c-JUN-JNK interaction inhibitor. c-JUN peptide inhibits serum-induced c-Jun phosphorylation. c-JUN peptide induces apoptosis .
    c-JUN peptide
  • HY-P3816
    PKCε Inhibitor Scramble Peptide

    		PKC Others
    PKCε Inhibitor Scramble Peptide is a scrambled peptide with identical amino acid composition to PKCε inhibitor peptide.
    PKCε Inhibitor Scramble Peptide
  • HY-P4133
    MEK1 Derived Peptide Inhibitor 1

    		ERK MEK Cancer
    MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by MEK1 with an IC50 value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .
    MEK1 Derived Peptide Inhibitor 1
  • HY-P5884A
    PKCθ pseudosubstrate peptide inhibitor,myristoylated TFA

    		PKC Others
    PKCθ pseudosubstrate peptide inhibitor, myristoylated TFA is a synthetic peptide that can be used to study the mechanism of action of PKCθ .
    PKCθ pseudosubstrate peptide inhibitor,myristoylated TFA
  • HY-P5881
    PKCα (C2-4) inhibitor peptide

    		PKC Cardiovascular Disease
    PKCα (C2-4) inhibitor peptide is a PKCα specific inhibitor peptide that blocks the inhibition of IKr by the α1A adrenoreceptor agonist A-61603 (HY-101366) .
    PKCα (C2-4) inhibitor peptide
  • HY-P5818
    BDS-II

    		Sodium Channel Neurological Disease
    BDS-II is a peptide toxin, and is composed of 43 amino acids. BDS-II is a selective Kv3.4 channel inhibitor .
    BDS-II
  • HY-161079
    TDI-8304

    		Parasite Infection
    TDI-8304, a macrocyclic peptide, is a potent, species selective, and noncovalent Plasmodium falciparum (Pf20S) inhibitor. TDI-8304 shows highly selective for Pf20S over human proteasomes .
    TDI-8304
  • HY-P1386
    D15

    Dynamin II (828–842)

    		 iGluR Neurological Disease
    D15, a peptide with 15 aa segment of dynamin, is an AMPAR endocytosis inhibitor. D15 blocks the interaction of dynamin with amphiphysin 1 and 2. D15 significantly increases AMPAR excitatory postsynaptic potential (EPSC) amplitude of medium spiny neurons (MSNs) in Sapap3 KO mice. D15 can be used for neuropsychiatric disorder research .
    D15
  • HY-P11224
    RMI-L4

    		DNA/RNA Synthesis Cancer
    RMI-L4 is an efficient cyclic peptide inhibitor that can specifically disrupt the interaction between FANCM and RMI proteins with an IC50 of 54 nM. RMI-L4 engages the FANCM-binding pocket of RMI1/2 with nanomolar affinity (KD = 2.5 nM). RMI-L4 cannot penetrate the cell membrane and can be used to study the FANCM-RMI pathway targeting cancer with alternate lengthening of telomeres (ALT) .
    RMI-L4
  • HY-P11038
    IL-23 cyclic peptide inhibitor 105

    		Interleukin Related Inflammation/Immunology
    IL-23 cyclic peptide inhibitor 105, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 105 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .
    IL-23 cyclic peptide inhibitor 105
  • HY-P11039
    IL-23 cyclic peptide inhibitor 281

    		Interleukin Related Inflammation/Immunology
    IL-23 cyclic peptide inhibitor 281, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 281 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .
    IL-23 cyclic peptide inhibitor 281
  • HY-P3199
    PKCβII Peptide Inhibitor I

    		PKC Inflammation/Immunology
    PKCβII Peptide Inhibitor I is a PKCβII inhibitor. PKCβII Peptide Inhibitor I shows cardioprotective effects in rat cardiac Ischemia/reperfusion injury model. PKCβII Peptide Inhibitor I also prevents vascular endothelial dysfunction .
    PKCβII Peptide Inhibitor I
  • HY-P1111A
    Lyn peptide inhibitor TFA

    		Src Interleukin Related Inflammation/Immunology
    Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor TFA blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor TFA can be used for study of  asthma, allergic, and other eosinophilic disorders .
    Lyn peptide inhibitor TFA
  • HY-P10837
    LAG-3 cyclic peptide inhibitor 12

    		LAG-3 Inflammation/Immunology Cancer
    LAG-3 cyclic peptide inhibitor 12 (Cyclic peptide 12) is an inhibitor of LAG-3 with an IC50 value of 4.45 μM and a Ki value of 2.66 µM .
    LAG-3 cyclic peptide inhibitor 12
  • HY-P10835
    LAG-3 cyclic peptide inhibitor C25

    		LAG-3 Cancer
    LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 + T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .
    LAG-3 cyclic peptide inhibitor C25
  • HY-P10422
    Multi-Leu peptide

    ML-peptide, Multi-Leucine (ML)-peptide

    		 Autophagy Cancer
    Multi-Leu peptide (ML-peptide) is a potent inhibitor of PACE4 (Ki=22 nM). Multi-Leu peptide can competitively bind to the active site of PACE4 by simulating the substrate sequence of PACE4, thereby inhibiting its catalytic activity. Multi-Leu peptide can be used to study the specific mechanism of PACE4 in the development of prostate cancer .
    Multi-Leu peptide
  • HY-P10818
    Polyglutamine binding peptide 1

    		Huntingtin Neurological Disease
    Polyglutamine binding peptide 1 (QBP1) is a peptide inhibitor of polyglutamine (polyQ). Polyglutamine binding peptide 1 inhibits polyQ protein aggregation in vitro and suppresses polyQ-induced cell death in cell culture .
    Polyglutamine binding peptide 1
  • HY-P11006
    Onc112

    		Bacterial Infection
    Onc112 is a proline-rich antimicrobial peptide that displays potent activity against Gram-negative bacteria. Onc112 inhibits translation by blocking and destabilizing the initiation complex .
    Onc112

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: